What Should You Think of the New Abbott Labs?

The new year has come, and Abbott Labs' (NYSE: ABT  ) spinoff of its branded pharmaceuticals division into the new company AbbVie (NYSE: ABBV  ) is complete. AbbVie is getting all of the attention from analysts at the moment because of its powerhouse arthritis drug, Humira, which generates the bulk of the revenue for the company -- but what about Abbott Labs? In this video, Motley Fool health care bureau chief Brenton Flynn tells us what he thinks of the trimmer new Abbott sans the branded pharmaceuticals, and why it reminds him a lot of Johnson & Johnson (NYSE: JNJ  ) .


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2450146, ~/Articles/ArticleHandler.aspx, 7/30/2014 6:05:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement